Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

• Published in: Blood 2011-10, Vol.118 (17), p.4519-4529
• Main Authors: Palumbo, Antonio, Bringhen, Sara, Ludwig, Heinz, Dimopoulos, Meletios A., Bladé, Joan, Mateos, Maria V., Rosiñol, Laura, Boccadoro, Mario, Cavo, Michele, Lokhorst, Henk, Zweegman, Sonja, Terpos, Evangelos, Davies, Faith, Driessen, Christoph, Gimsing, Peter, Gramatzki, Martin, Hàjek, Roman, Johnsen, Hans E., Leal Da Costa, Fernando, Sezer, Orhan, Spencer, Andrew, Beksac, Meral, Morgan, Gareth, Einsele, Hermann, San Miguel, Jesus F., Sonneveld, Pieter
• Format: Article
• Language: English
• Subjects: Age Factors; Age of Onset; Aged; Aged, 80 and over; Biological and medical sciences; Community Networks; Europe; Frail Elderly; Hematologic and hematopoietic diseases; Humans; Immunodeficiencies. Immunoglobulinopathies; Immunoglobulinopathies; Immunopathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Medical sciences; Multiple Myeloma - epidemiology; Multiple Myeloma - therapy; Precision Medicine - methods; Vulnerable Populations - statistics & numerical data
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2011-06-358812

Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time because of an aging population. Most elderly patients with MM are ineligible for autologous transplantation, and the standard treatment has, until recently, been melphalan plus prednisone. The introduction of novel agents, such as thalidomide, bortezomib, and lenalidomide, has improved outcomes; however, elderly patients with MM are more susceptible to side effects and are often unable to tolerate full drug doses. For these patients, lower-dose-intensity regimens improve the safety profile and thus optimize treatment outcome. Further research into the best treatment strategies for vulnerable elderly patients is urgently needed. Appropriate screening for vulnerability and an assessment of cardiac, pulmonary, renal, hepatic, and neurologic functions, as well as age > 75 years, at the start of therapy allows treatment strategies to be individualized and drug doses to be tailored to improve tolerability and optimize efficacy. Similarly, occurrence of serious nonhematologic adverse events during treatment should be carefully taken into account to adjust doses and optimize outcomes.